Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Long-Term Deferred Tax (2025)

Neuphoria Therapeutics (NEUP) has disclosed Long-Term Deferred Tax for 1 consecutive years, with $26.1 million as the latest value for Q2 2025.

  • On a quarterly basis, Long-Term Deferred Tax changed N/A to $26.1 million in Q2 2025 year-over-year; TTM through Jun 2025 was $26.1 million, a N/A change, with the full-year FY2025 number at $26.1 million, changed N/A from a year prior.
  • Long-Term Deferred Tax was $26.1 million for Q2 2025 at Neuphoria Therapeutics.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $26.1 million in Q2 2025 to a low of $26.1 million in Q2 2025.